🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

20 results for “Apellis Europe B.V.” Clear

  1. APL-2

    Apellis Europe B.V.

    Geographic Atrophy

    phase 3 small molecule completed

    2 trials

  2. APL-2

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    1 trial

  3. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  4. APL2

    Apellis Europe B.V.

    FSGS

    phase 3 small molecule active

    1 trial

  5. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  6. Pegcetacoplan

    Apellis Europe B.V.

    C3G

    phase 3 small molecule active

    3 trials

  7. Pegcetacoplan

    Apellis Europe B.V.

    PNH

    phase 3 small molecule active

    2 trials

  8. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  9. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  10. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  11. APL-2

    Apellis Europe B.V.

    IgA Nephropathy

    phase 2 small molecule completed

    1 trial

  12. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial

  13. APL-9

    Apellis Europe B.V.

    COVID

    phase 2 small molecule completed

    1 trial

  14. Pegcetacoplan

    Apellis Europe B.V.

    Transplant-Associated Thrombotic Microangiopathy

    phase 2 small molecule completed

    1 trial

  15. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    2 trials

  16. Pegcetacoplan

    Apellis Europe B.V.

    Neovascular Age-related Macular Degeneration

    phase 2 small molecule terminated

    2 trials

  17. Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy

    phase 2 small molecule completed

    1 trial

  18. Pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  19. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy

    phase 1 small molecule completed

    1 trial

  20. Virtual Reality (VR) Contrast Function Test

    Apellis Europe B.V.

    Age-Related Macular Degeneration

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources